{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:44:21Z","timestamp":1793400261235,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cll.2025.01.011","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:35:04Z","timestamp":1742373304000},"page":"283-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Detecting Xylazine"],"prefix":"10.1016","volume":"45","author":[{"given":"Katie M.","family":"Troike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cll.2025.01.011_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/pnasnexus\/pgae050","article-title":"Forecasting drug-overdose mortality by age in the United States at the national and county levels","volume":"3","author":"B\u00f6ttcher","year":"2024","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.cll.2025.01.011_bib2","doi-asserted-by":"crossref","first-page":"S359","DOI":"10.1097\/PHH.0000000000001580","article-title":"The overdose response strategy: reducing drug overdose deaths through strategic partnership between public health and public safety","volume":"28","author":"Wolff","year":"2022","journal-title":"J Public Health Manag Pract"},{"key":"10.1016\/j.cll.2025.01.011_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2196\/56755","article-title":"Barriers to, and facilitators of, checking drugs for adulterants in the era of fentanyl and xylazine: qualitative study","volume":"8","author":"Aronson","year":"2024","journal-title":"JMIR Form Res"},{"key":"10.1016\/j.cll.2025.01.011_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0033354919887741","article-title":"The emerging role of toxic adulterants in street drugs in the US illicit opioid crisis","volume":"135","author":"Singh","year":"2019","journal-title":"Public Health Rep"},{"key":"10.1016\/j.cll.2025.01.011_bib6","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","article-title":"Xylazine and overdoses: trends, concerns, and recommendations","volume":"112","author":"Alexander","year":"2022","journal-title":"Am J Public Health"},{"key":"10.1016\/j.cll.2025.01.011_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2885.1988.tb00189.x","article-title":"Xylazine--a review of its pharmacology and use in veterinary medicine","volume":"11","author":"Sa","year":"1988","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1016\/j.cll.2025.01.011_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ADM.0000000000001132","article-title":"Widespread distribution of xylazine detected throughout the United States in healthcare patient samples","volume":"17","author":"Holt","year":"2023","journal-title":"J Addict Med"},{"key":"10.1016\/j.cll.2025.01.011_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11524-011-9662-6","article-title":"The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico","volume":"89","author":"Reyes","year":"2012","journal-title":"J Urban Health"},{"key":"10.1016\/j.cll.2025.01.011_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.drugalcdep.2008.03.005","article-title":"GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles","volume":"96","author":"Rodr\u00edguez","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.cll.2025.01.011_bib12","first-page":"1","article-title":"Prevalence of xylazine among people who inject drugs seeking medical care at a syringe services program clinic: Miami, Florida, 2023","volume":"9","author":"Hauschild","year":"2023","journal-title":"Drug Alcohol Depend Rep"},{"key":"10.1016\/j.cll.2025.01.011_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-021-00546-9","article-title":"Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications","volume":"18","author":"Bowles","year":"2021","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.cll.2025.01.011_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jflm.2023.102542","article-title":"The first drug-related death associated with xylazine use in the UK and Europe","volume":"97","author":"Rock","year":"2023","journal-title":"J Forensic Leg Med"},{"key":"10.1016\/j.cll.2025.01.011_bib20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3109\/15563658108990293","article-title":"Human xylazine overdose: a comparative review with clonidine, phenothiazines, and tricyclic antidepressants","volume":"18","author":"Gallanosa","year":"1981","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.cll.2025.01.011_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11916-024-01211-z","article-title":"Xylazine: a drug adulterant of clinical concern","volume":"28","author":"Edinoff","year":"2024","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.cll.2025.01.011_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jat\/25.4.245","article-title":"Severe intoxication with the veterinary tranquilizer xylazine in humans","volume":"25","author":"Hoffmann","year":"2001","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.cll.2025.01.011_bib23","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jaad.2023.04.009","article-title":"Skin ulcerations caused by xylazine: a lesser-known entity","volume":"89","author":"Bishnoi","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cll.2025.01.011_bib24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2885.1981.tb00715.x","article-title":"The pharmacokinetics of xylazine hydrochloride: an interspecific study","volume":"4","author":"Garcia-Villar","year":"1981","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1016\/j.cll.2025.01.011_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","article-title":"Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature","volume":"240","author":"Ruiz-Col\u00f3n","year":"2014","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.cll.2025.01.011_bib26","doi-asserted-by":"crossref","first-page":"9779","DOI":"10.1007\/s00216-013-7419-7","article-title":"Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC\u2013MS, LC\u2013MSn, and LC\u2013HR-MSn","volume":"405","author":"Meyer","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.cll.2025.01.011_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jpba.2003.12.007","article-title":"Determination of xylazine and its metabolites by GC\u2013MS in equine urine for doping analysis","volume":"35","author":"Spyridaki","year":"2004","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.cll.2025.01.011_bib28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/jat\/bkv040","article-title":"Simultaneous determination of xylazine and 2,6-xylidine in blood and urine by auto solid-phase extraction and ultra high performance liquid chromatography coupled with quadrupole-time of flight mass spectrometry","volume":"39","author":"Gao","year":"2015","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.cll.2025.01.011_bib29","unstructured":"Reyes AG, Walton SE, Debord J, et al. Urine drug surveillance in Philadelphia, PA, with emphasis on xylazine and its metabolites. Presented at: society of forensic toxicologists annual meeting; 2023; Denver, CO."},{"key":"10.1016\/j.cll.2025.01.011_bib30","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/1556-4029.13270","article-title":"Attempted drug-facilitated sexual assault-xylazine intoxication in a child","volume":"62","author":"Andresen-Streichert","year":"2017","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.cll.2025.01.011_bib31","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/1556-4029.13684","article-title":"Use of xylazine in drug-facilitated crimes","volume":"63","author":"Krongvorakul","year":"2018","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.cll.2025.01.011_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.cll.2025.01.011_bib33","first-page":"1","article-title":"Perspectives of people in Philadelphia who use fentanyl\/heroin adulterated with the animal tranquilizer xylazine; Making a case for xylazine test strips","volume":"4","author":"Reed","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"key":"10.1016\/j.cll.2025.01.011_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/PAF.0000000000000622","article-title":"Xylazine, a veterinary tranquilizer, detected in 42 accidental fentanyl intoxication deaths","volume":"42","author":"Nunez","year":"2021","journal-title":"Am J Forensic Med Pathol"},{"key":"10.1016\/j.cll.2025.01.011_bib35","first-page":"481","article-title":"Reducing the harms of xylazine: clinical approaches, research deficits, and public health context","volume":"20","author":"Zagorski","year":"2023","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.cll.2025.01.011_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/toxics11121012","article-title":"Xylazine poisoning in clinical and forensic practice: analysis method, characteristics, mechanism and future challenges","volume":"11","author":"Mai","year":"2023","journal-title":"Toxics"},{"key":"10.1016\/j.cll.2025.01.011_bib37","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00213-023-06390-y","article-title":"Xylazine effects on opioid-induced brain hypoxia","volume":"240","author":"Choi","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.cll.2025.01.011_bib38","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMp2303120","article-title":"Xylazine \u2014 medical and public health imperatives","volume":"388","author":"Gupta","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cll.2025.01.011_bib39","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00063110-200309000-00022","article-title":"Drug abuse with inhalated xylazine","volume":"10","author":"Elejalde","year":"2003","journal-title":"Eur J Emerg Med"},{"key":"10.1016\/j.cll.2025.01.011_bib40","article-title":"What you should know about xylazine","year":"2024","journal-title":"Overdose Prevention"},{"key":"10.1016\/j.cll.2025.01.011_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cca.2021.07.010","article-title":"High prevalence of xylazine among fentanyl screen-positive urines from hospitalized patients, Philadelphia, 2021","volume":"521","author":"Korn","year":"2021","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"10.1016\/j.cll.2025.01.011_bib42","doi-asserted-by":"crossref","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","article-title":"Illicitly manufactured fentanyl-involved overdose deaths with detected xylazine - United States, January 2019-June 2022","volume":"72","author":"Kariisa","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cll.2025.01.011_bib43","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm7217a2","article-title":"Rapid analysis of drugs: a pilot surveillance system to detect changes in the illicit drug supply to guide timely harm reduction responses - eight syringe services programs, Maryland, November 2021-August 2022","volume":"72","author":"Russell","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cll.2025.01.011_bib44","article-title":"Xylazine in drug seizure reports and overdose deaths in the US, 2018\u20132022","author":"Cano","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.cll.2025.01.011_bib45","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/dta.1475","article-title":"Case report of accidental poisoning with the tranquilizer xylazine and the anesthetic ketamine confirmed by qualitative and quantitative toxicological analysis using GC-MS and LC-MS","volume":"5","author":"Meyer","year":"2013","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.cll.2025.01.011_bib46","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1556-4029.2007.00648.x","article-title":"Concurrent detection of heroin, fentanyl, and xylazine in seven drug-related deaths reported from the Philadelphia Medical Examiner\u2019s Office","volume":"53","author":"Wong","year":"2008","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.cll.2025.01.011_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2024.124059","article-title":"A quantitative LC-MS\/MS analysis of Xylazine, p-fluorofentanyl, Fentanyl and Fentanyl-Related compounds in postmortem blood","volume":"1237","author":"Truver","year":"2024","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.cll.2025.01.011_bib48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/jat\/bkae009","article-title":"Analysis of over 250 novel synthetic opioids and xylazine by LC\u2013MS-MS in blood and urine","volume":"48","author":"Diekhans","year":"2024","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.cll.2025.01.011_bib49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/jat\/31.3.165","article-title":"Solid-phase extraction and gas chromatographic-mass spectrometric determination of the veterinary drug xylazine in human blood","volume":"31","author":"Barroso","year":"2007","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.cll.2025.01.011_bib50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/jat\/bks024","article-title":"Simultaneous determination of xylazine, free morphine, codeine, 6-acetylmorphine, cocaine and benzoylecgonine in postmortem blood by UPLC\u2013MS-MS","volume":"36","author":"Ruiz-Col\u00f3n","year":"2012","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.cll.2025.01.011_bib51","first-page":"pp1","article-title":"Xylazine awareness, desire, use and exposure: preliminary findings from the Rhode Island community-based drug checking cohort study","volume":"11","author":"Park","year":"2024","journal-title":"Drug Alcohol Depend Rep"},{"key":"10.1016\/j.cll.2025.01.011_bib52","unstructured":"Farry L, O\u2019Loan N, Porter J, et al. Development of a novel xylazine ELISA for the rapid screening of xylazine in human whole blood and urine samples. Presented at: Society of Forensic Toxicologists Annual Meeting; 2023; Denver, CO."},{"key":"10.1016\/j.cll.2025.01.011_bib53","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/jat\/bkae043","article-title":"Evaluation of the ARK Diagnostics immunoassay for qualitative detection of xylazine in urine","volume":"48","author":"Kyle","year":"2024","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.cll.2025.01.011_bib54","first-page":"1","article-title":"Xylazine test strips for drug checking: CADTH horizon scan","volume":"7","author":"Jones","year":"2023","journal-title":"Canadian Journal of Health Technologies"},{"key":"10.1016\/j.cll.2025.01.011_bib55","first-page":"1","article-title":"Understanding sensitivity and cross-reactivity of xylazine lateral flow immunoassay test strips for drug checking applications","volume":"15","author":"Sisco","year":"2023","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.cll.2025.01.011_bib56","first-page":"1","article-title":"Pilot findings on the real-world performance of xylazine test strips for drug residue testing and the importance of secondary testing methods","volume":"11","author":"Thompson","year":"2024","journal-title":"Drug Alcohol Depend Rep"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271225000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271225000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:46:00Z","timestamp":1746773160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271225000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0272271225000125"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2025.01.011","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detecting Xylazine","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2025.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}